The neutropenia biologic drug treatment market consists of sales of biologics used for the treatment of neutropenia and related services by entities (organizations, sole traders and partnerships) that produce biologics for neutropenia treatment. Neutropenia is a clinical condition characterized by a decrease in neutrophil count in the blood, resulting in a higher risk of developing serious infections. A neutrophil is a type of white blood cell, which helps in fighting infections. The major causes of neutropenia include cancer chemotherapy, infections, bone marrow disorders, autoimmune disorders, and the use of specific drugs. The market consists of revenue generated by the companies manufacturing the neutropenia biologic drugs by the sales of these products.
The global neutropenia biologic drug treatment market is expected to decline from $12.22 billion in 2019 to $11.54 billion in 2020 at a compound annual growth rate (CAGR) of -5.54%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $13.34 billion in 2023 at a CAGR of 4.95%.